DSP 6952

Drug Profile

DSP 6952

Alternative Names: DSP-6952

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sumitomo Dainippon Pharma
  • Class Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation; Irritable bowel syndrome

Most Recent Events

  • 31 Jan 2017 Phase-II clinical trials in Constipation in Japan (PO) before January 2017 (Sumitomo Dainippon Pharma pipline, January 2017)
  • 01 Nov 2016 Dainippon Sumitomo Pharma initiates a phase II trial for Irritable bowel syndrome (in patients with constipation) in Japan (PO) (JapicCTI163459)
  • 14 Jan 2016 Phase II development is ongoing for Constipation and Irritable bowed syndrome with constipation in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top